NRXP RSI Chart
Last 7 days
15.8%
Last 30 days
-15.8%
Last 90 days
-25.3%
Trailing 12 Months
-48.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 310.3K | 371.5K | 432.8K | 494.0K |
2022 | 2.5M | 1.4M | 0 | 249.0K |
2021 | 0 | 0 | 0 | 3.7M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Aug 30, 2023 | gorovitz aaron | bought | 11,196 | 0.3199 | 35,000 | - |
Aug 30, 2023 | hurvitz chaim | bought | 20,125 | 0.2875 | 70,000 | - |
Aug 23, 2023 | javitt jonathan c | bought | 33,000 | 0.33 | 100,000 | chief scientist |
Aug 22, 2023 | javitt jonathan c | bought | 64,400 | 0.322 | 200,000 | chief scientist |
Dec 16, 2022 | van voorhees seth | bought | 33,000 | 1.1 | 30,000 | chief financial officer |
Dec 16, 2022 | willard stephen h | bought | 58,500 | 1.17 | 50,000 | chief executive officer |
Dec 14, 2022 | javitt jonathan c | gifted | - | - | -300,000 | - |
Dec 07, 2022 | javitt jonathan c | sold | -400,000 | 1.00 | -400,000 | - |
Nov 30, 2022 | javitt daniel c. | sold | -12,700 | 1.5046 | -8,441 | - |
Nov 29, 2022 | javitt daniel c. | sold | -20,651 | 1.5041 | -13,730 | - |
Which funds bought or sold NRXP recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | new | - | 13,065 | 13,065 | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | 1,360 | 53,910 | -% |
May 15, 2024 | MORGAN STANLEY | reduced | -0.87 | 345 | 20,739 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -34.00 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | unchanged | - | 1.00 | 3.00 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 8.78 | 1,053 | 10,113 | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | 1,460 | 57,902 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -99.92 | -69,000 | - | -% |
May 14, 2024 | Qube Research & Technologies Ltd | unchanged | - | 2.00 | 78.00 | -% |
May 14, 2024 | AdvisorShares Investments LLC | reduced | -4.33 | -5,490 | 290,121 | 0.05% |
Unveiling NRx Pharmaceuticals, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to NRx Pharmaceuticals, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
NRx Pharmaceuticals, Inc. News
Income Statement (Quarterly) | |||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Revenue | -53.9% | 481,000 | 1,043,333 | 1,605,667 | 2,168,000 | 351,000 | 175,500 | - | 2,020,000 | 2,844,500 | 3,669,000 |
Operating Expenses | 36.1% | 5,998,000 | 4,406,000 | 5,808,000 | 8,188,000 | 9,435,000 | 9,888,500 | 9,600,000 | 15,705,000 | 52,975,000 | 20,099,000 |
S&GA Expenses | -100.0% | - | 1,872,000 | 2,494,000 | 4,065,000 | 5,785,000 | 5,432,000 | 6,642,000 | 10,222,000 | 51,641,000 | 13,823,000 |
R&D Expenses | -31.0% | 1,748,000 | 2,534,000 | 3,314,000 | 3,873,000 | 3,650,000 | 4,456,500 | 2,958,000 | 5,483,000 | 6,413,000 | 6,276,000 |
EBITDA Margin | 0% | -80.22 | -80.22 | -91.84 | -106 | -128 | -159 | -66.99 | -36.79 | -25.36 | - |
Interest Expenses | 367.5% | 374,000 | 80,000 | 40,000 | - | - | - | - | 3,000 | 2,500 | 5,000 |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | - | - | - | - | - | - | - | - | - | -30,407,181 | -37,049,331 |
EBT Margin | 0% | -80.47 | -80.47 | -91.86 | -107 | -128 | -159 | -67.00 | -36.80 | -25.36 | - |
Net Income | -50.7% | -6,528,000 | -4,332,000 | -6,062,000 | -8,717,000 | -11,039,000 | -10,241,000 | -6,982,000 | -13,448,000 | -30,407,500 | -37,049,000 |
Net Income Margin | 15.0% | -51.90 | -61.03 | -83.33 | -105 | -120 | -159 | -63.27 | -32.04 | -25.36 | - |
Free Cashflow | -15.0% | -3,671,000 | -3,192,000 | -4,564,000 | -7,812,000 | -6,089,000 | -8,318,000 | -14,791,000 | -10,380,000 | -11,280,000 | -12,014,000 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -48.2% | 4.00 | 7.00 | 13.00 | 20.00 | 22.00 | 26.00 | 25.00 | 32.00 | 44.00 | 33.00 | 45.00 | 19.00 | 14.00 | 3.00 | 6.00 | 6.00 | 6.00 | 24.00 | 42.00 | 50.00 | 72.00 |
Current Assets | -51.4% | 3.00 | 7.00 | 13.00 | 20.00 | 22.00 | 26.00 | 25.00 | 32.00 | 44.00 | 33.00 | 45.00 | 19.00 | 14.00 | 3.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 |
Cash Equivalents | -71.3% | 1.00 | 5.00 | 9.00 | 15.00 | 17.00 | 20.00 | 18.00 | 25.00 | 40.00 | 28.00 | 39.00 | 13.00 | 13.00 | 2.00 | 1.00 | 1.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 |
Liabilities | -1.0% | 19.00 | 19.00 | 19.00 | 23.00 | 22.00 | 18.00 | 8.00 | 7.00 | 12.00 | 12.00 | 37.00 | 58.00 | 7.00 | 47.00 | 3.00 | 3.00 | 2.00 | 6.00 | 2.00 | 2.00 | 2.00 |
Current Liabilities | -100.0% | - | 19.00 | 19.00 | 23.00 | 22.00 | 16.00 | - | - | - | 12.00 | 37.00 | 58.00 | 7.00 | 46.00 | 0.00 | 0.00 | 0.00 | 2.00 | 1.00 | 1.00 | 0.00 |
Shareholder's Equity | -28.4% | -15.07 | -11.73 | - | - | -0.28 | 7.00 | 17.00 | 25.00 | 32.00 | 21.00 | 8.00 | - | 6.00 | 2.00 | 3.00 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 5.00 |
Retained Earnings | -2.6% | -259 | -253 | -248 | -242 | -234 | -223 | -212 | -203 | -196 | -183 | -152 | -115 | -115 | -90.18 | 0.00 | 0.00 | 1.00 | -38.40 | 0.00 | 0.00 | 0.00 |
Additional Paid-In Capital | 1.4% | 245 | 241 | 243 | 240 | 234 | 230 | 229 | 229 | 228 | 204 | 161 | 76.00 | 122 | 46.00 | 3.00 | 3.00 | 3.00 | 34.00 | 5.00 | 5.00 | 5.00 |
Shares Outstanding | 14.0% | 10.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 5.00 | 4.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 30.00 | - | 34,952,532 | - | 40,584,788 | - | - | - | 187 | - | - | - | 6.00 | - | - | - | 50.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -15.0% | -3,671 | -3,192 | -4,564 | -7,812 | -6,089 | -8,318 | -6,266 | -14,791 | -10,380 | -11,280 | -12,014 | -11,394 | -3,015 | -406 | -1,130 | 104 | -832 | -5,011 | -52.31 | -180 | -297 |
Share Based Compensation | 120.1% | 242 | -1,203 | 351 | 544 | 695 | 766 | 541 | 987 | 1,334 | 1,570 | 1,560 | 4,283 | 372 | 357 | 191 | 93.00 | 89.00 | - | - | - | - |
Cashflow From Investing | -100.0% | - | 1.00 | -2.00 | 2.00 | -4.00 | 1.00 | -5.00 | -3.00 | -3.00 | - | -4.00 | -3.00 | - | -26,211 | 306 | -23.22 | 25,926 | -30,606 | 8,931 | 22,179 | -508 |
Cashflow From Financing | 135.4% | 395 | -1,116 | -1,501 | 6,273 | 2,545 | 10,122 | -28.00 | -860 | 22,980 | 1.00 | 37,516 | 11,512 | 14,427 | 980 | 1,422 | 620 | 227 | 35,691 | -8,686 | -21,999 | 797 |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 299 | - | 25,998 | -30,990 | 8,891 | 22,099 | - |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expense: | ||
Research and development | $ 1,748 | $ 3,650 |
General and administrative | 4,250 | 5,785 |
Total operating expenses | 5,998 | 9,435 |
Loss from operations | (5,998) | (9,435) |
Other (income) expense: | ||
Interest income | (27) | (156) |
Interest expense | 230 | |
Change in fair value of convertible note payable | 318 | 1,772 |
Change in fair value of warrant liabilities | 9 | (12) |
Total other expense | 530 | 1,604 |
Net loss | (6,528) | (11,039) |
Comprehensive (income) loss: | ||
Change in fair value of convertible note attributed to credit risk | (106) | |
Other comprehensive income | (106) | |
Comprehensive loss | $ (6,528) | $ (10,933) |
Net loss per share: | ||
Basic | $ (0.74) | $ (1.66) |
Diluted | $ (0.74) | $ (1.66) |
Weighted average common shares outstanding: | ||
Basic | 8,852,286 | 6,647,391 |
Diluted | 8,852,286 | 6,647,391 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 1,319 | $ 4,595 |
Prepaid expense and other current assets | 2,028 | 2,289 |
Total current assets | 3,347 | 6,884 |
Other assets | 441 | 431 |
Total assets | 3,788 | 7,315 |
Current liabilities: | ||
Accounts payable | 6,265 | 4,632 |
Accrued and other current liabilities | 5,296 | 4,714 |
Accrued clinical site costs | 491 | 524 |
Convertible note payable and accrued interest | 6,779 | 9,161 |
Warrant liabilities | 26 | 17 |
Total liabilities | 18,857 | 19,048 |
Commitments and Contingencies (Note 8) | ||
Stockholders' deficit: | ||
Preferred stock, value | ||
Common stock, $0.001 par value, 500,000,000 shares authorized; 9,772,672 and 8,391,940 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 10 | 8 |
Additional paid-in capital | 244,599 | 241,406 |
Accumulated other comprehensive loss | (3) | (3) |
Accumulated deficit | (259,675) | (253,147) |
Total stockholders' deficit | (15,069) | (11,733) |
Total liabilities and stockholders' deficit | $ 3,788 | 7,315 |
Series A Convertible Preferred Stock | ||
Stockholders' deficit: | ||
Preferred stock, value | $ 3 |